fidzu : geek

In a small double-blind clinical trial, a single intravenous dose of DMT produced rapid and clinically meaningful reductions in symptoms of major depressive disorder within a week, with effects lasting up to three months in some patients. "Unlike psilocybin and lysergic acid diethylamide ( LSD), whose effects can last for hours, intravenous DMT has a half-life of around five minutes," notes ScienceAlert. "Its psychedelic effects are correspondingly brief, potentially making it more practical to administer in clinical settings." From the report: "A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to three months," writes a team led by neuroscientists David Erritzoe and Tommaso Barba of Imperial College London. [...] They recruited 34 participants with major depression and divided them into two groups of 17 for a double-blind, placebo-controlled trial. In the first stage of the trial, one group received an intravenous dose of DMT, while the other received an active placebo. Neither the researchers nor the participants were informed which participants received the DMT. The doses took around 10 minutes to administer, and a therapist sat with each participant to ensure comfort and safety while the psychedelic effects were active, remaining silent throughout the treatment. The treatment was generally well tolerated. Most side effects were mild to moderate, and included nausea, temporary anxiety, and pain at the injection site. No serious adverse events related to the treatment were reported, although brief increases in heart rate and blood pressure were observed immediately after dosing. In the second, open-label stage, two weeks after the first dose, all participants were given the opportunity to receive a dose of DMT. Participants were assessed before and at intervals after each dose using the Montgomery-Asberg Depression Rating Scale. Just a week after the first dose, participants who had received DMT had improved scores compared to the placebo group, and improvements were sustained during follow-up assessments. Two weeks after the first dose, the participants who received DMT scored about seven points lower, on average, than those who received a placebo. On this commonly used clinical scale, a drop of that size is generally considered a meaningful reduction in symptom severity. There was no significant difference between patients who received one or two doses of DMT, suggesting a single dose may be sufficient. These effects persisted for up to three months, and some patients remained in remission for at least six months following the treatment. The findings have been published in Nature Medicine.

Read more of this story at Slashdot.

18 Feb 2026 10:00am GMT

Longtime Slashdot reader walterbyrd shares a report from ABC News: In a study of nearly 28 million older Americans, long-term exposure to fine particle air pollution raised the risk of Alzheimer's disease. That link held even after researchers accounted for common conditions like high blood pressure, stroke and depression. Fine particle air pollution, known as PM2.5, consists of tiny particles in the air that come from car exhaust, power plants, wildfires, and burning fuels, according to the American Lung Association. They are small enough to travel deep into the lungs and even reach the bloodstream. The research, conducted at Emory University and published in PLOS Medicine, tracked health data over nearly two decades to explore whether air pollution harms the brain indirectly by causing high blood pressure or heart disease, which, in turn, leads to dementia. However, these "middleman" conditions accounted for less than 5% of the connection between pollution and Alzheimer's, the research found. The researchers say this suggests that over 95% of the Alzheimer's risk comes from the direct impact of breathing in dirty air, likely through inflammation or damage to brain cells. "The relationship between PM2.5 and AD [Alzheimer's disease] has been shown to be pretty much linear," said Kyle Steenland, a professor in the departments of environmental health and epidemiology at the Rollins School of Public Health at Emory University, and senior author of the study. "The reason this is particularly important is that PM2.5 is known to be associated with high blood pressure, stroke and depression -- all of which are associated with AD. So, from a prevention standpoint, simply treating these diseases will not get rid of the problem. We have to address exposure to PM2.5."

Read more of this story at Slashdot.

18 Feb 2026 7:00am GMT

An anonymous reader quotes a report from the Associated Press: Agrochemical maker Bayer and attorneys for cancer patients announced a proposed $7.25 billion settlement Tuesday to resolve thousands of U.S. lawsuits alleging the company failed to warn people that its popular weedkiller Roundup could cause cancer. The proposed settlement comes as the U.S. Supreme Court is preparing to hear arguments in April on Bayer's assertion that the U.S. Environmental Protection Agency's approval of Roundup without a cancer warning should invalidate claims filed in state courts. That case would not be affected by the proposed settlement. But the settlement would eliminate some of the risk from an eventual Supreme Court ruling. Patients would be assured of receiving settlement money even if the Supreme Court rules in Bayer's favor. And Bayer would be protected from potentially larger costs if the high court rules against it. Germany-based Bayer, which acquired Roundup maker Monsanto in 2018, disputes the assertion that Roundup's key ingredient, glyphosate, can cause non-Hodgkin lymphoma. But the company has warned that mounting legal costs are threatening its ability to continue selling the product in U.S. agricultural markets. "Litigation uncertainly has plagued the company for years, and this settlement gives the company a road to closure," Bayer CEO Bill Anderson said Tuesday. The proposed settlement could total up to $7.25 billion over 21 years and resolve most of the remaining U.S. lawsuits surrounding the cancer-related harms of Roundup. The report notes that more than 125,000 claims have been filed since 2015, and while many have already been settled, this deal aims to cover most outstanding and future claims tied to past exposure. Individual payouts would vary widely based on exposure type, age at diagnosis, and cancer severity. Bayer can also cancel the deal if too many plaintiffs opt out.

Read more of this story at Slashdot.

18 Feb 2026 3:30am GMT

KDE Plasma 6.6 has been released, and brings with a whole slew of new features. You can save any combination of themes as a global theme, and there's a new feature allowing you to increase or decrease the contrast of frames and outlines. If your device has a camera, you can now scan Wi-F settings from QR codes, which is quite nice if you spend a lot of time on the road. There's a new colour filter for people who are colour blind, allowing you to set the entire UI to grayscale, as well as a brand new virtual keyboard. Other new accessibility features include tracking the mouse cursor when using the zoom feature, a reduced motion setting, and more. Spectacle gets a text extraction feature and a feature to exclude windows from screen recordings. There's also a new optional login manager, optimised for Wayland, a new first-run setup wizard, and much more. As always, KDE 6.6 will find its way to your distribution's repositories soon enough.

18 Feb 2026 12:07am GMT

SvarDOS is an open-source project that is meant to integrate the best out of the currently available DOS tools, drivers and games. DOS development has been abandoned by commercial players a long time ago, mostly during early nineties. Nowadays it survives solely through the efforts of hobbyists and retro-enthusiasts, but this is a highly sparse and unorganized ecosystem. SvarDOS aims to collect available DOS software and make it easy to find and install applications using a network-enabled package manager (like apt-get, but for DOS and able to run on a 8086 PC). ↫ SvarDOS website SvarDOS is built around a fork of the Enhanced DR-DOS kernel, which is available in a dedicated GitHub repository. The project's base installation is extremely minimal, containing only the kernel, a command interpreter, and some basic system administration tools, and this basic installation is compatible down to the 8086. You are then free to add whatever packages you want, either from local storage or from the online repository using the included package manager. SvarDOS is a rolling release, and you can use the package manager to keep it updated. Aside from a set of regular installation images for a variety of floppy sizes, there's also a dedicated "talking" build that uses the PROVOX screen reader and Braille 'n Speak synthesizer at the COM1 port. It's rare for a smaller project like this to have the resources to dedicate to accessibility, so this is a rather pleasant surprise.

17 Feb 2026 11:30pm GMT

GameHub's existing Windows emulator on Android has its fair share of issues.

17 Feb 2026 10:45pm GMT

It's been a while since we've talked about AsteroidOS, the Linux distribution designed specifically to run on smartwatches, providing a smartwatch interface and applications built with Qt and QML. The project has just released version 2.0, and it comes with a ton of improvements. AsteroidOS 2.0 has arrived, bringing major features and improvements gathered during its journey through community space. Always-on-Display, expanded support for more watches, new launcher styles, customizable quick settings, significant performance increases in parts of the User Interface, and enhancements to our synchronization clients are just some highlights of what to expect. ↫ AsteroidOS 2.0 release announcement I'm pleasantly surprised by how many watches are actually fully supported by AsteroidOS 2.0; especially watches from Fossil and Ticwatch are a safe buy if you want to run proper Linux on your wrist. There are also synchronisation applications for Android, desktop Limux, Sailfish OS, and UBports Ubuntu Touch. iOS is obviously missing from this list, but considering Apple's stranglehold on iOS, that's not unexpected. Then again, if you bought into the Apple ecosystem, you knew what you were getting into. As for the future of the project, they hope to add a web-based flashing tool and an application store, among other things. I'm definitely intrigued, and am now contemplating if I should get my hands on a (used) supported watch to try this out. Anything I can move to Linux is a win.

17 Feb 2026 10:34pm GMT

Contrary to what password managers say, a server compromise can mean game over.

17 Feb 2026 8:43pm GMT

Colbert: "I want to assure you this decision is for purely financial reasons."

17 Feb 2026 7:01pm GMT

On Friday, July 18th, 2025, the Arch Linux team was notified that three AUR packages had been uploaded that contained malware. A few maintainers including myself took care of deleting these packages, removing all traces of the malicious code, and protecting against future malicious uploads.

30 Jan 2026 12:00am GMT

While starting this post I realized I have been maintaining personal infrastructure for over a decade! Most of the things I've self-hosted is been for personal uses. Email server, a blog, an IRC server, image hosting, RSS reader and so on. All of these things has all been a bit all over the place and never properly streamlined. Some has been in containers, some has just been flat files with a nginx service in front and some has been a random installed Debian package from somewhere I just forgot.

19 Jan 2026 12:00am GMT

In the recent blog post on the work funded by Sovereign Tech Fund (STF), we provided an overview of the "File Hierarchy for the Verification of OS Artifacts" (VOA) and the voa project as its reference implementation. VOA is a generic framework for verifying any kind of distribution artifacts (i.e. files) using arbitrary signature verification technologies. The voa CLI ⌨️ The voa project offers the voa(1) command line interface (CLI) which makes use of the voa(5) configuration file format for technology backends. It is recommended to read the respective man pages to get …

11 Jan 2026 12:00am GMT